Edesa Biotech (EDSA)
NASDAQ:EDSA
Want to see EDSA full AI Analyst Report?
EDSA Stock Chart & Stats
$1.48
>-$0.01(-0.02%)
At close: 4:00 PM EST
$1.48
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$0.72 - $20.32
Previous CloseN/A
Volume1.31K
Average Volume (3M)850.36K
Market Cap
$60.73M
Enterprise Value$54.20M
Total Cash (Recent Filing)$10.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.70
Next Earnings
Aug 07, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding8,891,951
10 Day Avg. Volume370,294
30 Day Avg. Volume850,362
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-526.25
Enterprise Value/Ebitda-5.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetLow financial leverage and roughly $12.4M of equity materially reduce near-term solvency risk and provide an asset base to support operations. Over the next 2-6 months this balance-sheet strength gives the company time to advance clinical programs without immediate default risk.
Focused Clinical-Stage PipelineA concentrated pipeline targeting inflammatory and immune-related diseases creates a clear strategic focus and potential for high-impact clinical readouts. Structural demand for immuno-inflammatory therapies supports long-term commercial opportunity if clinical milestones are met.
Cash-Conserving, Incentive-Aligned CompensationShifting a large portion of executive pay into equity reduces recurring cash outflows and conserves runway. The stronger equity linkage aligns management incentives with shareholder value creation, a durable governance mechanism during extended R&D cycles.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow of roughly -$7.6M TTM signifies ongoing cash consumption tied to R&D. Over months this burn rate necessitates fresh financing or cost cuts and constrains strategic optionality absent near-term milestone-driven inflows.
Minimal Revenue; Large Net LossesWith virtually no product revenue and a sizeable recurring net loss, the company lacks operating cash generation and depends on pipeline success. This business profile leaves enterprise value highly binary and sensitive to clinical outcomes rather than stable commercial performance.
Reliance On Equity FinancingDependence on issuing equity to fund operations is structurally dilutive and can erode existing shareholders' stakes over time. Repeated capital raises are likely while development continues, limiting long-term return predictability without clear near-term milestones.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech’s price range in the past 12 months?
Edesa Biotech lowest stock price was $0.72 and its highest was $20.32 in the past 12 months.
What is Edesa Biotech’s market cap?
Edesa Biotech’s market cap is $60.73M.
When is Edesa Biotech’s upcoming earnings report date?
Edesa Biotech’s upcoming earnings report date is Aug 07, 2026 which is in 63 days.
How were Edesa Biotech’s earnings last quarter?
Edesa Biotech released its earnings results on May 14, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.26 by -$0.23.
Is Edesa Biotech overvalued?
According to Wall Street analysts Edesa Biotech’s price is currently Overvalued.
Does Edesa Biotech pay dividends?
Edesa Biotech does not currently pay dividends.
What is Edesa Biotech’s EPS estimate?
Edesa Biotech’s EPS estimate is -0.63.
How many shares outstanding does Edesa Biotech have?
Edesa Biotech has 8,891,951 shares outstanding.
What happened to Edesa Biotech’s price movement after its last earnings report?
Edesa Biotech reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.26. Following the earnings report the stock price went down -10.678%.
Which hedge fund is a major shareholder of Edesa Biotech?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
EDSA Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $232.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
244.72%
12-Months-Change
Fundamentals
Return on Equity
-82.34%
Trailing 12-Months
Asset Growth
-24.73%
Trailing 12-Months
Company Description
Edesa Biotech
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
21.60% Insiders
1.41% Mutual Funds
24.25% Other Institutional Investors
51.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---